Immunyx
PrivateLast Round
Grant
Jun 1, 2024
Company Overview
Immunyx is a biotechnology company developing a targeted neutrophil nanoparticle platform to treat chronic diseases like cancer and arthritis.
Sector
Cybersecurity
Verticals
Application Security, Vulnerability Management, Cloud Security, Compliance & Risk, Threat Intelligence
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Government Contracts, Freemium
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunyx Comparables
Compare Immunyx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LIfT Biosciences | 77% | |
| Neutrolis Inc | 71% | |
| Jubilant Pharmova Limited | 51% |
Immunyx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 1, 2024 | ||||
| Grant | Sep 1, 2023 | ||||
| Accelerator | Jan 23, 2023 | ||||
| Seed | Mar 1, 2021 |
Key People
Founding team and executive leadership
Immunyx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Biomedical Advanced Research and Development Authority | Accelerator, Grant |
| VLX Ventures | Seed |
| Johnson & Johnson Innovation - JLABS | Accelerator |
| Johnson & Johnson Innovation - JJDC, Inc. | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 20, 2025
Monthly visitors increased 887% MoM.
- Jun 1, 2024
Received funding from Johnson & Johnson Innovation and BARDA.
Immunyx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access